Screener
Taysha Gene Therapies, Inc. TSHA Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Taysha Gene Therapies, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: Taysha Gene Therapies, Inc.’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344610
FAQ
- What is Taysha Gene Therapies, Inc.'s accounts payable?
- Taysha Gene Therapies, Inc. (TSHA) reported accounts payable of $9.16M in Q2 2026.
- How has Taysha Gene Therapies, Inc.'s accounts payable changed year-over-year?
- Taysha Gene Therapies, Inc.'s accounts payable increased by 18.8% year-over-year, from $7.71M to $9.16M.
- What is the long-term trend for Taysha Gene Therapies, Inc.'s accounts payable?
- Over 4 years (2021 to 2025), Taysha Gene Therapies, Inc.'s accounts payable has grown at a -18.7% compound annual growth rate (CAGR), from $54.25M to $23.75M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about Taysha Gene Therapies, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude